Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623103 · ClinicalTrials.gov registry record · Phase 3
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
NCT00623103: Completed Phase 3 study, sponsored by Novartis.
NCT00623103 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 583 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00623103, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
Study Summary
The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's Disease (PD), in patients with mild to moderately severe dementia associated with PD.
Primary Outcome
The AEs were summarized by presenting the number and percentage of patients having any of the 4 AEs or discontinued due to any of the 4 predefined AEs (tremor, muscle rigidity, bradykinesia, and fall)in each treatment group. The 95% CIs associated with the rates were also presented.
Interventions
- DRUG Rivastigmine transdermal patch
- DRUG Rivastigmine capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 2008-01 |
| Phase | Phase 3 |
What the finished NCT00623103 record still lists
NCT00623103 is an interventional study that assigns participants to a tested intervention. The registered 583 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 2 interventions - of which Rivastigmine transdermal patch is the first listed.
NCT00623103 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00623103 about?
NCT00623103 is a clinical study titled "Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)". The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's Disease (PD), in patients with mild to moderately severe dementia associated ...
What is the current status of trial NCT00623103?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 2008-01.
What interventions are being tested in trial NCT00623103?
The interventions under investigation include: Rivastigmine transdermal patch (DRUG), Rivastigmine capsule (DRUG).
Who is sponsoring clinical trial NCT00623103?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00623103's enrollment target sits among peer trials
583 652nd of 2000 higher than 1,348 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
- NCT04984291 · 584 participants · NA
Zimmer Biomet Shoulder Arthroplasty PMCF
- NCT05983757 · 584 participants · NA
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
- NCT06569290 · 584 participants · NA
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia